DE3587899T2 - Transkriptionsfaktoren mit transaktivität. - Google Patents

Transkriptionsfaktoren mit transaktivität.

Info

Publication number
DE3587899T2
DE3587899T2 DE3587899T DE3587899T DE3587899T2 DE 3587899 T2 DE3587899 T2 DE 3587899T2 DE 3587899 T DE3587899 T DE 3587899T DE 3587899 T DE3587899 T DE 3587899T DE 3587899 T2 DE3587899 T2 DE 3587899T2
Authority
DE
Germany
Prior art keywords
transactivity
transaction factors
transaction
factors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE3587899T
Other languages
English (en)
Other versions
DE3587899D1 (de
Inventor
William Haseltine
Joseph Sodroski
Craig Rosen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dana Farber Cancer Institute Inc
Original Assignee
Dana Farber Cancer Institute Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dana Farber Cancer Institute Inc filed Critical Dana Farber Cancer Institute Inc
Publication of DE3587899D1 publication Critical patent/DE3587899D1/de
Application granted granted Critical
Publication of DE3587899T2 publication Critical patent/DE3587899T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00Reverse transcribing RNA viruses
    • C12N2740/00011Details
    • C12N2740/10011Retroviridae
    • C12N2740/14011Deltaretrovirus, e.g. bovine leukeamia virus
    • C12N2740/14022New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00Reverse transcribing RNA viruses
    • C12N2740/00011Details
    • C12N2740/10011Retroviridae
    • C12N2740/16011Human Immunodeficiency Virus, HIV
    • C12N2740/16311Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DE3587899T 1984-05-25 1985-05-24 Transkriptionsfaktoren mit transaktivität. Expired - Fee Related DE3587899T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US06/614,297 US4738922A (en) 1984-05-25 1984-05-25 Trans-acting transcriptional factors
PCT/US1985/000985 WO1985005636A1 (en) 1984-05-25 1985-05-24 Trans-acting transcriptional factors

Publications (2)

Publication Number Publication Date
DE3587899D1 DE3587899D1 (de) 1994-09-15
DE3587899T2 true DE3587899T2 (de) 1995-03-30

Family

ID=24460645

Family Applications (1)

Application Number Title Priority Date Filing Date
DE3587899T Expired - Fee Related DE3587899T2 (de) 1984-05-25 1985-05-24 Transkriptionsfaktoren mit transaktivität.

Country Status (6)

Country Link
US (2) US4738922A (de)
EP (1) EP0181929B1 (de)
JP (1) JP2518609B2 (de)
AU (1) AU4430885A (de)
DE (1) DE3587899T2 (de)
WO (1) WO1985005636A1 (de)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60169498A (ja) * 1984-02-10 1985-09-02 Kyowa Hakko Kogyo Co Ltd 成人t細胞白血病ウイルス抗原ペプチド誘導体
US9309574B1 (en) 1984-08-22 2016-04-12 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Molecular cloning of HIV-1 from immortalized cell lines
CA1341482C (en) * 1984-10-31 2005-05-10 Paul A. Luciw Process for preparing fragments of aids-associated retroviruses
US5801056A (en) * 1985-05-24 1998-09-01 Dana-Farber Cancer Institute Nucleic acid encoding HIV-1 tat protein
WO1987005048A1 (en) * 1986-02-14 1987-08-27 United States Of America, Represented By The Unite Plasmids which inhibit human t-cell lymphotropic virus type iii replication
US5604114A (en) * 1986-05-20 1997-02-18 Dana-Farber Cancer Institute Cis-acting repression sequences, cis-acting antirepression sequences, vectors, methods of preparation and use
WO1988007083A1 (en) * 1987-03-13 1988-09-22 Schering Corporation Method for stimulating gene expression
US4935363A (en) * 1987-03-30 1990-06-19 Board Of Regents, The University Of Texas System Sterol regulatory elements
US5215910A (en) * 1987-03-27 1993-06-01 Board Of Regents, The University Of Texas Host cells transformed with sterol regulatory elements
US5378603A (en) * 1987-03-30 1995-01-03 Board Of Regents, The University Of Texas System Method and composition for identifying substances which activate transcription of the LDL receptor gene
US5256545A (en) * 1987-03-30 1993-10-26 Board Of Regents, The University Of Texas System Sterol Regulatory Elements
EP0291893A1 (de) * 1987-05-19 1988-11-23 The Du Pont Merck Pharmaceutical Company Stabile menschliche Zellinien, die ein Indikatorgenprodukt unter virusspezifischen genetischen Kontrollen exprimieren
DE3854313D1 (de) * 1987-05-29 1995-09-21 Dana Farber Cancer Inst Inc Cis-Wirkung-Repressionen-Sequenzen, Cis-Wirkung-Antirepressionen-Sequenzen, Vektoren, Verfahren zur Vorbereitung und Anwendung.
US5024939A (en) * 1987-07-09 1991-06-18 Genentech, Inc. Transient expression system for producing recombinant protein
EP0299127A1 (de) * 1987-07-16 1989-01-18 IntraCel Corporation Verfahren zur Expression von Rekombinantgenen, stimuliert von einem induzierbaren exprimierten Aktivatorprotein
US5688655A (en) * 1988-02-10 1997-11-18 Ict Pharmaceuticals, Inc. Method of screening for protein inhibitors and activators
US4952499A (en) * 1988-02-11 1990-08-28 Dana-Farber Cancer Institute Genes and their encoded proteins which regulate gene expression of the interleukin-2 receptor and of human lymphotropic retroviruses
US5149785A (en) * 1988-02-11 1992-09-22 Dana-Farber Cancer Institute Proteins which regulate gene expression of the interleukin-2 receptor and of human lymphotropic retroviruses
US6241982B1 (en) 1988-03-21 2001-06-05 Chiron Corporation Method for treating brain cancer with a conditionally lethal gene
US6133029A (en) 1988-03-21 2000-10-17 Chiron Corporation Replication defective viral vectors for infecting human cells
US5716826A (en) * 1988-03-21 1998-02-10 Chiron Viagene, Inc. Recombinant retroviruses
US6569679B1 (en) 1988-03-21 2003-05-27 Chiron Corporation Producer cell that generates adenoviral vectors encoding a cytokine and a conditionally lethal gene
US5662896A (en) 1988-03-21 1997-09-02 Chiron Viagene, Inc. Compositions and methods for cancer immunotherapy
US5070012A (en) * 1988-03-30 1991-12-03 The Board Of Trustees Of The Leland Stanford Junior University Monitoring of cells and trans-activating transcription elements
JPH04503300A (ja) * 1988-10-06 1992-06-18 デイナ・フアーバー・キヤンサー・インステイテユート H.saimiri―htlv―x領域ベクター
WO1990005787A1 (en) * 1988-11-23 1990-05-31 The Regents Of The University Of California Position-specific insertion vectors and method of using same
GB8827592D0 (en) * 1988-11-25 1988-12-29 Taniguchi T Improvements in & relating to regulation of expression
US5217867A (en) * 1988-11-30 1993-06-08 The Salk Institute For Biological Studies Receptors: their identification, characterization, preparation and use
ATE174514T1 (de) * 1989-01-23 1999-01-15 Chiron Corp Rekombinante zellen für therapien von infektionen und hyperprolieferative störungen und deren herstellung
WO1990007936A1 (en) * 1989-01-23 1990-07-26 Chiron Corporation Recombinant therapies for infection and hyperproliferative disorders
US5278042A (en) * 1989-02-06 1994-01-11 The United States Of America As Represented By The Department Of Health & Human Services Method for detecting inhibitors of tat protein
US6251675B1 (en) * 1989-05-25 2001-06-26 Duke University Methods utilizing mutant rev genes encoding transdominant repressors of HIV replication
US5871958A (en) * 1989-05-25 1999-02-16 Duke University Mutant rev genes encoding transdominant repressors of HIV replication
US5665543A (en) 1989-07-18 1997-09-09 Oncogene Science, Inc. Method of discovering chemicals capable of functioning as gene expression modulators
EP0483249B1 (de) * 1989-07-18 2003-04-23 OSI Pharmaceuticals, Inc. Methode der veränderung der expression von genen bei der transkription und zum nachweis von chemischen substanzen, die wie modulatoren der genexpression wirken
US5776502A (en) 1989-07-18 1998-07-07 Oncogene Science, Inc. Methods of transcriptionally modulating gene expression
US6203976B1 (en) * 1989-07-18 2001-03-20 Osi Pharmaceuticals, Inc. Methods of preparing compositions comprising chemicals capable of transcriptional modulation
US5580722A (en) * 1989-07-18 1996-12-03 Oncogene Science, Inc. Methods of determining chemicals that modulate transcriptionally expression of genes associated with cardiovascular disease
FR2651005B1 (fr) * 1989-08-17 1992-01-03 Pasteur Institut Lignees de cellules infectables par un retrovirus et contenant un marqueur activable a l'occasion de l'infection
ATE212672T1 (de) * 1989-10-24 2002-02-15 Chiron Corp System zur freisetzung von infektiösen proteinen
US5070010A (en) * 1989-10-30 1991-12-03 Hoffman-La Roche Inc. Method for determining anti-viral transactivating activity
GB9003010D0 (en) * 1990-02-09 1990-04-04 Glaxo Group Ltd Gene expression in yeast cells
IT1241123B (it) * 1990-04-19 1993-12-29 Consiglio Nazionale Ricerche Cellule umane per l'elevata espressione di geni inseriti in dna ricombinanti episomiali,loro preparazione e loro impiego
EP0455424A3 (en) * 1990-05-02 1992-04-29 Merck & Co. Inc. Mammalian inducible promoter cascade system
US5364783A (en) * 1990-05-14 1994-11-15 Massachusetts Institute Of Technology Retrovirus promoter-trap vectors
AU1150792A (en) * 1990-12-06 1992-07-08 United States of America, as represented by the Secretary, U.S. Department of Commerce, The Inhibition of human immunodeficiency virus by an adeno-associated virus gene for human cells
WO1992013091A1 (en) * 1991-01-18 1992-08-06 Oncogene Science, Inc. Methods of transcriptionally modulating expression of oncogenes and tumor suppressor genes
AU1347292A (en) * 1991-01-18 1992-08-27 Oncogene Science, Inc. Methods of transcriptionally modulating gene expression of viral genes and other genes
WO1992013092A1 (en) * 1991-01-18 1992-08-06 Oncogene Science, Inc. Methods of transcriptionally modulating expression of hematopoietic growth factor genes
AU1469292A (en) * 1991-01-18 1992-08-27 Oncogene Science, Inc. Methods of transcriptionally modulating expression of growth factor genes and growth factor receptor genes
CA2044940A1 (en) * 1991-06-10 1992-12-11 Inder M. Verma Transdominant negative proto-oncogene
WO1993008844A1 (fr) * 1991-10-30 1993-05-13 Universite Pierre Et Marie Curie (Paris Vi) Cellules transformees pour la prevention ou le traitement de maladies induites par des virus, notamment retrovirus pathogenes
ES2049691T3 (es) * 1992-03-13 2000-10-16 Monsanto Co Produccion de proteinas recombinantes utilizando promotores del virus herpes y transactivadores vp16.
WO1995014091A2 (en) 1993-11-18 1995-05-26 Chiron Viagene, Inc. Compositions and methods for utilizing conditionally lethal genes
US5888814A (en) * 1994-06-06 1999-03-30 Chiron Corporation Recombinant host cells encoding TNF proteins
US5733781A (en) * 1994-07-19 1998-03-31 Gen-Probe Incorporated Oligonucleotides and methods for inhibiting propagation of human immunodeficiency virus
US6344543B1 (en) 1997-04-22 2002-02-05 Human Genome Sciences, Inc. Human transcription factor IIA
GB9510272D0 (en) * 1995-05-22 1995-07-19 Isis Innovation Retroviral vectors
US5990091A (en) * 1997-03-12 1999-11-23 Virogenetics Corporation Vectors having enhanced expression, and methods of making and uses thereof
US5891994A (en) * 1997-07-11 1999-04-06 Thymon L.L.C. Methods and compositions for impairing multiplication of HIV-1
US7189402B1 (en) * 1998-02-06 2007-03-13 Research Development Foundation Live vaccine for human immunodeficiency virus
US6399067B1 (en) * 2000-04-28 2002-06-04 Thymon L.L.C. Methods and compositions for impairing multiplication of HIV-1
KR101347830B1 (ko) 2004-05-23 2014-01-07 에이치엠아이, 인코포레이티드 테라뮤틴 조절물질
US20060174362A1 (en) * 2005-02-01 2006-08-03 Origen Therapeutics, Inc. Long-term culture of avian primordial germ cells (PGCs)
EP1851247A2 (de) 2005-02-15 2007-11-07 Thymon L.L.C. Verfahren und zusammensetzungen zur behinderung der vervielfältigung von hiv-1
US8431110B2 (en) 2005-05-23 2013-04-30 Hmi Medical Innovations, Llc. Compounds and method of identifying, synthesizing, optimizing and profiling protein modulators
US20090275070A1 (en) * 2005-11-23 2009-11-05 Housey Gerard M Compounds and Methods of Identifying, Synthesizing, Optimizing and Profiling Protein Modulators

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4405712A (en) * 1981-07-01 1983-09-20 The United States Of America As Represented By The Department Of Health And Human Services LTR-Vectors

Also Published As

Publication number Publication date
AU4430885A (en) 1985-12-31
US4981790A (en) 1991-01-01
DE3587899D1 (de) 1994-09-15
EP0181929A4 (de) 1988-04-27
US4738922A (en) 1988-04-19
JPS61502793A (ja) 1986-12-04
WO1985005636A1 (en) 1985-12-19
EP0181929B1 (de) 1994-08-10
EP0181929A1 (de) 1986-05-28
JP2518609B2 (ja) 1996-07-24

Similar Documents

Publication Publication Date Title
DE3587899T2 (de) Transkriptionsfaktoren mit transaktivität.
NO167321C (no) Roerkobling.
NO853415L (no) Roerledning-utlegningsfartoey.
FI843385A (fi) Anordning i virvelbaeddsreaktor.
FI860122A (fi) Flat paneldisplayenhet utnyttjande en linjeformad faeltemissionskatodgrupp.
FI852228A0 (fi) Foerbaettrad utrustning foer automatisk svetsning av roer.
FI842455A0 (fi) Foerbindning foer roer med kragad aende.
FI845087L (fi) Faestuppstaellning foer en skaerkonstruktion i en motorsaog.
FI850085L (fi) Aendaggregat foer extrusionsmunstycket i en plastpelleteringsanordning.
FI842051A (fi) Daempningsventil foer kopplingen i en traktors kraftoeverfoeringsaxel.
FI853785A0 (fi) Anordning foer vaermeisolering av underjordiska roer.
FI843081A (fi) Dubbelviraformare i pappersmaskin.
FI850203A0 (fi) Anordning i maxtermostat foer kombinationspanna.
FI842050A0 (fi) Banformningsparti i pappersmaskin.
NO882166L (no) Roerledning-utlegningsfartoey.
FI852918L (fi) Faestmuff foer roer.
FI844169A (fi) Plan paolsko.
FI840883A (fi) Roeranslutning foer roer av betong.
FI843504A (fi) Vaexelanordning foer kedjehjulens inboerdes rotationshastighet i kedjetransmission.
FI843658L (fi) Brandplaot foer luftkanalerna i en ventilationsanordning.
FI843304A0 (fi) Vridmekanism foer spjaelor i jalusier.
FI843102A0 (fi) Foer anvaendning i noejespark avsedd transpartanordning.
FI841278A0 (fi) I lastkorg monterad transportoer.
FI841673A0 (fi) Oeppnings- och laosningsuppstaellning foer en bakport i en avfallsbil.
FI841924A0 (fi) Uppstaellning i en vaexellaoda.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee